Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Accelerate to discover
Related topics
Vizgen webinar: spatial relationships in Developmental Biology
Nov 21, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, In this webinar we will...
Nov 14, 2023
The xCELLigence RTCA eSight enables simultaneous real time biosensor impedance-based and...
NanoCellect webinar: Plant Potential - Gentle Cell Sorting for Enhanced Plant Biology Workflows
Nov 3, 2023
Gentle cell sorting is a useful tool to increase the efficiency of plant biology workflows that include gene...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Nov 2, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Emulate in vivo conditions – introduce shear flow to your experiments with BioFlux system
Oct 31, 2023
Most research is still conducted in vitro without the presence of flow. We use the BioFlux System to give you the...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Oct 30, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Validation of an orthotopic non-small cell lung cancer mouse model to use in radiotherapy studies
Oct 30, 2023
The use of pre-clinical orthotopic mouse models is essential for the development of novel therapies targeting solid...
Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy
Oct 20, 2023
To assess tumour growth, mice were imaged using the AMI-HTX bioluminescent imaging system (Spectral Instruments...
Mar 6, 2017
Pheochromocytomas (PHEOs) and extra-adrenal paragangliomas (PGLs) are rare adrenaline-producing tumors. The two tumor types are closely related and are distinguished primarily by their location: pheochromocytomas occur in the center of the adrenal glands while extra-adrenal paragangliomas originate in the paraganglia of the sympathetic nervous system (most commonly in the abdomen). Extra-adrenal paragangliomas are less common, but more likely to be malignant, than pheochromocytomas.
Diagnosis of metastatic PHEOs/PGLs is difficult and tends to rely on identification of adrenaline/noradrenaline production in areas where adrenaline/noradrenaline is not normally produced. Furthermore, such metastases are notoriously difficult to treat. A variety of chemotherapy combinations and radiotherapy are used as palliative treatment, but complete remission is rare.
Consequently, the mouse pheochromocytoma mCherry tumor allograft model was developed, which is functionally similar to human PHEO/PGLs. This mouse model has recently been used to assess the value of the [177Lu]Lu-DOTA-(Tyr3)octreotate (DOTATATE), a labeled somatostatin receptor analog, as a targeted therapy for metastatic PHEO/PGLs in man. And this study confirms that the mCherry model is a uniquely powerful tool for evaluating therapeutic or diagnostic agents that specifically target the somatostatin-2 receptor.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Get more info
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com